human cancer News
-
Summary of IARC Working Group Meeting on Some Nanomaterials and Some Fibers Published
The International Agency for Research on Cancer (IARC) Working Group met on September 30-October 7, 2014, to review the carcinogenicity of fluoro-edenite, silicon carbide (SiC) fibers and whiskers, and carbon nanotubes (CNT). A summary of the evaluations has now been published in The Lancet Oncology. The summary states: Fluoro-edenite fibrous amphibole was classified as carcinogenic to humans ...
-
NIEHS Scientists Identify the Immunity Proteins that cause a majority of DNA Damage in Several Types of Human Cancers
New research published online August 10 in the journal Nature Genetics found that a mutation-causing enzyme known at APOBEC3A (A3A) may be the main cause of mutations in certain cancers. Previous work from other groups implicated another APOBEC enzyme, known as APOBEC3B (A3B). Corresponding author Dmitry Gordenin, Ph.D., head of the NIEHS Mechanisms of Genome Dynamics Group, will be available ...
-
Biosceptre welcomes Tuspark S & T into its Series A fund raising round
Biosceptre has received over £8M into its’ series A raise which will be used to resource the next stage of the companies’ development; progression into the clinic of Biosceptre’s first systemic products against novel oncology target nfP2X7. Biosceptre will close the series A on the 21st December, 2017. The major portion of the raise received to date was led by Tuspark ...
-
Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology’s Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with Immunotherapy
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), notes findings by a team of physician-scientists led by principal investigator Dr. Amir Jazaeri, professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, and reported at the annual meeting of Society of Gynecologic Oncology (SGO) in Phoenix, AZ, that a subset of patients with ovarian clear ...
-
Biosceptre Joins European Cooperation in Science & Technology COST Group BMBS 1406 – with focus on Ion Channels and Immune Response
Biosceptre announces today its membership of the COST Group (European Cooperation in Science & Technology) project COST BMBS 1406. This project, established in 2014, created the Ion chan-Immune response network that brings together internationally recognised scientists and companies across 15 European countries with the common goal of understanding the function of ion channels in Bimmune ...
-
Can herbicides increase pancreatic cancer risk?
There is only a small chance of recovering from pancreatic cancer. This type of cancer has been linked to a number of risk factors, including smoking, but a new study suggests that pancreatic cancer may also be associated with exposure to certain herbicides. Other risk factors, in addition to smoking, that have been associated with a greater chance of developing pancreatic cancer include ...
-
Virometix Announces Completion of Initial Vaccination of the First Dose Cohort in Phase 1 Study with V-306
Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, announced today the completion of initial vaccination of the first dose cohort in the Phase 1 healthy volunteer study of V-306, its candidate vaccine for prophylaxis of RSV (Respiratory Syncytial Virus) ...
By Virometix AG
-
Pesticides linked to childhood brain cancers
There is much grey matter surrounding causes of brain cancer in children, but there is increasing evidence indicating that a culprit may be pre-birth pesticide exposure. In a new study released by the National Institute of Health Sciences, herbicide use appeared to cause an elevated risk for cancer. The study found that children living in homes where their parents use pesticides are twice as ...
-
Safety of sunscreen pigments comes under scrutiny
A new study shows how titanium dioxide nanoparticles used in sunscreens may cause cancer in mice. Although there is no proof that the nanoparticles can cause cancer in humans, the researchers say the study raises concerns about the safety of workers exposed to high concentrations of the nanoparticles in factory settings. Titanium dioxide is widely used in pigment production - it turns paints, ...
-
Berkeley Lab news release: Berkeley scientists find new way to get physical in the fight against cancer
Conventional biological wisdom holds that living cells interact with their environment through an elaborate network of chemical signals. As a result many therapies for the treatment of cancer and other diseases in which cell behavior goes awry focus on drugs that block or disrupt harmful chemical signals. Now, a new road for future therapies may have been opened with scientific evidence for a ...
-
ELIAS Animal Health Announces First Patient Enrolled in Clinical Trial for ECI™ for the Treatment of Canine B-Cell Lymphoma
ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, today announced the initiation of a clinical trial to determine the safety and efficacy of ELIAS Cancer Immunotherapy (ECI™), as a treatment for B-cell lymphoma in dogs. The majority of canine lymphomas are derived from B cells. While lymphoma is one of the most responsive ...
-
Berkeley lab awarded $12.8 million in stimulus funds for health research
Lawrence Berkeley National Laboratory has been awarded $12.8 million in American Recovery and Reinvestment Act funding by the National Institutes of Health (NIH) for research into cancer, neurodegenerative diseases, radioactive decontamination and a variety of other health conditions. The grants bring Berkeley Lab’s total Recovery Act funding to more than $240 million in areas covering energy, ...
-
New Paper Shows Biostage`s Esophageal Implant Regenerates the Esophagus in Piglets
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company with successful "first-in-human" experience in esophageal cancer and FDA approval to commence a clinical trial of its Biostage Esophageal Implant for esophageal disease, today announced the publication of paper establishing the basis for using its product to treat birth defects in the esophagus in babies. The ...
-
NIH Study Offers Insight into Why Cancer Incidence Increases with Age
The accumulation of age-associated changes in a biochemical process that helps control genes may be responsible for some of the increased risk of cancer seen in older people, according to a National Institutes of Health study. Scientists have known for years that age is a leading risk factor for the development of many types of cancer, but why aging increases cancer risk remains unclear. ...
-
Alpha-1 Biologics Announces Positive Data Published in frontiers in Oncology on Alphataxin in Combination with Anti-PD-1 Therapy that Suppressed Murine Renal Cancer and Metastasis
Alpha-1 Biologics, a biotherapeutics company developing innovative treatments for cancers and immune deficiencies, today announced that positive data was published in frontiers in Oncology demonstrating Alphataxin, a small molecule that elevates circulating and tumor-infiltrating CD4+ T cells, suppressed kidney cancer and suppressed metastasis in mice. Orally available Alphataxin, is the first ...
-
Tanning Gene Linked to Increased Risk of Testicular Cancer, According to NIH Scientists
A gene important in skin tanning has been linked to higher risk for testicular cancer in white men, according to a study led by scientists from the U.S. National Institutes of Health and the University of Oxford in England. Nearly 80 percent of white men carry a variant form of this gene, which increased risk of testicular cancer up to threefold in the study. The research appeared online October ...
-
Lixte Biotechnology Holdings, Inc. Announces that enrollment has resumed in national cancer institute’s trial to determine ability of Lixte compound lb-100 to enter recurrent, malignant brain tumors
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced that the National Cancer Institute (NCI) has resumed enrolling patients into their pharmacologic study of the ability of Lixte’s lead compound, LB-100, to enter the brain and penetrate recurrent, malignant brain tumors, in patients where surgical removal of their cancer is indicated. After enrolling two patients in the study, ...
-
Virometix Broadens Senior Leadership Team with Three Key Appointments
Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, today announced the expansion of its leadership team with the appointment of a Chief Scientific Officer and two additional Board members. Virometix filled a vacancy in its management team with the ...
By Virometix AG
-
Identifying Indoor Exposure Risks from VOCs in Residential and Commercial Properties across Puerto Rico
Volatile organic compounds (VOCs) are emitted from thousands of different products and building materials that can be found in businesses, homes and schools throughout Puerto Rico. These VOCs are emitted as gases from certain solids or liquids and can then inhaled by building occupants. VOCs include a variety of chemicals, some of which may have short- and long-term adverse health effects. ...
-
Groundwater measurements of herbicide may underestimate human exposure
Atrazine ranks as a common herbicide in the United States, where it’s frequently used to boost corn and sorghum yields by curbing weed growth. Conversely, the European Union has banned atrazine, which some research suggests can disrupt hormone production in wildlife and potentially humans. A 2021 study from the University of Nebraska Medical Center indicated that Nebraska counties ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you